



## Novel Adjuvants and Delivery Systems for Vaccines

Guest Editors:

**Dr. Christiane Chbib**

Department of Pharmaceutical  
Sciences, Larkin University,  
Miami, FL 33169, USA

**Dr. Mohammad N. Uddin**

Pharmaceutical Sciences,  
College of Pharmacy, Mercer  
University, Atlanta, GA 30341,  
USA

Deadline for manuscript  
submissions:

**31 March 2025**

### Message from the Guest Editors

Dear Colleagues,

Novel adjuvants and delivery systems for vaccines improve the quality of vaccine production by enhancing the immune response to a vaccine. Adjuvants can strengthen the immune system's response to the vaccine. Adjuvants have been traditionally used to increase the magnitude of the antibody response to a vaccine based on antibody titer or the ability to prevent infection and can guide the type of adaptive response to produce the most effective form of immunity. It is important to consider the construction of vaccine adjuvant delivery systems for both adjuvant activity and antigen delivery.

In this Special Issue, we will explore prospective novel adjuvant approaches to modify innate and adaptive immune responses to ease the development of enhanced prophylactic or therapeutic vaccines. We welcome contributions to vaccine adjuvant advances, immune enhancement mechanisms, rational design, immunostimulatory molecules, emulsions, liposomes, virosomes, and polymers with functional molecules.





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Ralph A. Tripp

Department of Infectious  
Diseases, College of Veterinary  
Medicine, University of Georgia,  
Athens, GA 30602-7387, USA

## Message from the Editor-in-Chief

*Vaccines* (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

## Author Benefits

**Open Access:** free for readers, with **article processing charges (APC)** paid by authors or their institutions.

**High Visibility:** indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPus / SciFinder, and other databases.**

**Journal Rank:** JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

## Contact Us

---

*Vaccines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/vaccines](http://mdpi.com/journal/vaccines)  
[vaccines@mdpi.com](mailto:vaccines@mdpi.com)